The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Anthracycline associated cardiotoxicity in survivors of childhood cancer
Abstract
The development of effective antineoplastic therapies for childhood cancer is a great success in modern medicine. Five year survival rates of children diagnosed with cancer in the USA and Western Europe in excess of 70% make long term survivors of childhood cancer a steadily increasing population. Although there is much to celebrate, new challenges lie ahead in treating the systemic sequelae of chemotherapy.1 Results from the Childhood Cancer Survivor Study (CCSS) showed that 30 years after treatment, the cumulative incidence of chronic health conditions in long term survivors reaches 73%, with a cumulative incidence of 42% for severe, disabling, or life threatening conditions or death.2 Severe conditions, that are significantly more common in childhood cancer survivors than in their siblings, include: major joint replacement (relative risk (RR) 54.0), congestive heart failure (RR 15.1), second malignant neoplasm (RR 14.8), severe cognitive dysfunction (RR 10.5), coronary artery disease (RR 10.4), cerebrovascular accident (RR 9.3), and renal failure (RR 8.9).2 Previous CCSS results found that patients who had survived at least 5 years after diagnosis had 10.8-fold increased rates of all cause mortality.3 The standardised mortality ratio for cardiac causes was 8.2 times higher than expected and the cumulative probability of cardiac death increased 15–25 years after cancer diagnosis. A similar study in a large Nordic cohort documented a standardised mortality ratio of 5.8 for cardiac death and elevated rates of sudden, presumed arrhythmic, deaths.4 Chief among adverse late effects is the cardiovascular toxicity of anthracyclines.5–11 Unfortunately, despite well documented dose related toxicity, the superior disease-free survival rates of regimens including anthracyclines leave limited viable treatment alternatives and the majority of long term paediatric cancer survivors in the Pediatric Oncology Group received an anthracycline during treatment.12 ### Mechanism of cardiotoxicity Several cytotoxic biochemical changes follow anthracycline exposure in …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N., Hobbie, W., Kadan-Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Self-citationCardinale, D., Colombo, A., Sandri, M. T., Lamantia, G., Colombo, N., Civelli, M., Martinelli, G., Veglia, F., Fiorentini, C., & Cipolla, C. M. (2006) · Circulation · doi:10.1161/circulationaha.106.635144 · Cited by 1,026
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Self-citationMertens, A. C., Yasui, Y., Neglia, J. P., Potter, J. D., Nesbit, M. E., Ruccione, K., Smithson, W. A., & Robison, L. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3163 · Cited by 798
Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Dalton, V. M., Mone, S. M., Gelber, R. D., & Colan, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.121 · Cited by 727
Self-citationProtective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy
Kalay, N., Basar, E., Ozdogru, I., Er, O., Cetinkaya, Y., Dogan, A., Oguzhan, A., Eryol, N. K., Topsakal, R., Ergin, A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.052 · Cited by 713
Enzymatic Defenses of the Mouse Heart Against Reactive Oxygen Metabolites
Doroshow, J. H., Locker, G. Y., & Myers, C. E. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109642 · Cited by 702
Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4976 · Cited by 634
Lipshultz, S. E., Rifai, N., Dalton, V. M., Levy, D. E., Silverman, L. B., Lipsitz, S. R., Colan, S. D., Asselin, B. L., Barr, R. D., Clavell, L. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035153 · Cited by 623
Self-citationSafra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000) · Annals of Oncology · doi:10.1023/a:1008365716693 · Cited by 618
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Carvedilol for Children and Adolescents With Heart Failure: A Randomized Controlled Trial
Shaddy, R. E., Boucek, M. M., Hsu, D. T., Boucek, R. J., Canter, C. E., Mahony, L., Ross, R. D., Pahl, E., Blume, E. D., Dodd, D. A., et al. (2007) · JAMA · doi:10.1001/jama.298.10.1171 · Cited by 570
Cardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H. O., & Kremer, L. C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003917.pub4 · Cited by 553
Krischer, J. P., Epstein, S., Cuthbertson, D. D., Goorin, A. M., Epstein, M. L., & Lipshultz, S. E. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1544 · Cited by 476
Self-citationCooper, L. T., Baughman, K. L., Feldman, A. M., Frustaci, A., Jessup, M., Kuhl, U., Levine, G. N., Narula, J., Starling, R. C., Towbin, J., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm456 · Cited by 464
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Self-citationWouters, K. A., Kremer, L. C. M., Miller, T. L., Herman, E. H., & Lipshultz, S. E. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05759.x · Cited by 453
Self-citationDaunomycin-induced cardiotoxicity in children and adults
Von Hoff, D. D., Rozencweig, M., Layard, M., Slavik, M., & Muggia, F. M. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90315-1 · Cited by 437
BRISTOW, M. R., MASON, J. W., BILLINGHAM, M. E., & DANIELS, J. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-2-168 · Cited by 417
Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury
Lipshultz, S. E., Rifai, N., Sallan, S. E., Lipsitz, S. R., Dalton, V., Sacks, D. B., & Ottlinger, M. E. (1997) · Circulation · doi:10.1161/01.cir.96.8.2641 · Cited by 384
Self-citationNew insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Epidemiology of anthracycline cardiotoxicity in children and adults.
Ma, G., & Se, L. (1998) · PubMed · Cited by 341
Lipshultz, S. E., Lipsitz, S. R., Sallan, S. E., Simbre, V. C., Shaikh, S. L., Mone, S. M., Gelber, R. D., & Colan, S. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.102 · Cited by 308
Self-citationAnthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Barry, E., Alvarez, J. A., Scully, R. E., Miller, T. L., & Lipshultz, S. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1039 · Cited by 307
Self-citationAnthracyclines Induce Calpain-dependent Titin Proteolysis and Necrosis in Cardiomyocytes
Lim, C. C., Zuppinger, C., Guo, X., Kuster, G. M., Helmes, M., Eppenberger, H. M., Suter, T. M., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308033200 · Cited by 304
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
Doxorubicin-induced apoptosis: Implications in cardiotoxicity
Kalyanaraman, B., Joseph, J., Kalivendi, S., Wang, S., Konorev, E., & Kotamraju, S. (2002) · Oxygen/Nitrogen Radicals: Cell Injury and Disease · doi:10.1007/978-1-4615-1087-1_13 · Cited by 296
Spallarossa, P., Garibaldi, S., Altieri, P., Fabbi, P., Manca, V., Nasti, S., Rossettin, P., Ghigliotti, G., Ballestrero, A., & Patrone, F. (2004) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.05.024 · Cited by 294
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Antioxidants and Cancer Therapy: A Systematic Review
Ladas, E. J., Jacobson, J. S., Kennedy, D. D., Teel, K., Fleischauer, A., & Kelly, K. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.086 · Cited by 260
Möller, T. R., Garwicz, S., Barlow, L., Winther, J. F., Glattre, E., Olafsdottir, G., Olsen, J. H., Perfekt, R., Ritvanen, A., Sankila, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3173 · Cited by 259
Cancer Incidence Among Children and Adolescents in the United States, 2001–2003
Li, J., Thompson, T. D., Miller, J. W., Pollack, L. A., & Stewart, S. L. (2008) · Pediatrics · doi:10.1542/peds.2007-2964 · Cited by 234
Adams, M. J., & Lipshultz, S. E. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20352 · Cited by 224
Self-citationAdriamycin-induced interference with cardiac mitochondrial calcium homeostasis
Wallace, K. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0008-2 · Cited by 221
Doxorubicin-induced persistent oxidative stress to cardiac myocytes
Zhou, S., Palmeira, C. M., & Wallace, K. B. (2001) · Toxicology Letters · doi:10.1016/s0378-4274(01)00329-0 · Cited by 219
Herman, E. H., Zhang, J., Lipshultz, S. E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z.-X., & Ferrans, V. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2237 · Cited by 210
Self-citationMeinardi, M. T., van Veldhuisen, D. J., Gietema, J. A., Dolsma, W. V., Boomsma, F., van den Berg, M. P., Volkers, C., Haaksma, J., de Vries, E. G. E., Sleijfer, D. T., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2746 · Cited by 207
Dolci, A., Dominici, R., Cardinale, D., Sandri, M. T., & Panteghini, M. (2008) · American Journal of Clinical Pathology · doi:10.1309/ajcpb66lriivmqdr · Cited by 205
Effect of exercise training on antioxidant enzymes and cardiotoxicity of doxorubicin
Kanter, M. M., Hamlin, R. L., Unverferth, D. V., Davis, H. W., & Merola, A. J. (1985) · Journal of Applied Physiology · doi:10.1152/jappl.1985.59.4.1298 · Cited by 202
Molecular and cellular mechanisms of anthracycline cardiotoxicity
Chen, B., Peng, X., Pentassuglia, L., Lim, C. C., & Sawyer, D. B. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0005-5 · Cited by 172
The cardiotoxicity of adriamycin and daunomycin in children
Gilladoga, A. C., Manuel, C., Tan, C. T. C., Wollner, N., Sternberg, S. S., & Murphy, M. L. (1976) · Cancer · doi:10.1002/1097-0142(197602)37:2+<1070::aid-cncr2820370814>3.0.co;2-6 · Cited by 171
(1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.6.976 · Cited by 167
Cardiotoxicity of Cancer Chemotherapy: Implications for Children
Simbre, V. C., Duffy, S. A., Dadlani, G. H., Miller, T. L., & Lipshultz, S. E. (2005) · Pediatric Drugs · doi:10.2165/00148581-200507030-00005 · Cited by 166
Self-citationGoorin, A. M., Chauvenet, A. R., Perez-Atayde, A. R., Cruz, J., McKone, R., & Lipshultz, S. E. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)81668-3 · Cited by 163
Self-citationLebrecht, D., Kokkori, A., Ketelsen, U., Setzer, B., & Walker, U. A. (2005) · The Journal of Pathology · doi:10.1002/path.1863 · Cited by 133
Barry, E. V., Vrooman, L. M., Dahlberg, S. E., Neuberg, D. S., Asselin, B. L., Athale, U. H., Clavell, L. A., Larsen, E. C., Moghrabi, A., Samson, Y., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2481 · Cited by 118
Self-citationLong-term effects of treatments for childhood cancers
Alvarez, J. A., Scully, R. E., Miller, T. L., Armstrong, F. D., Constine, L. S., Friedman, D. L., & Lipshultz, S. E. (2007) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328013c89e · Cited by 113
Self-citationCHEITLIN, M., ARMSTRONG, W., AURIGEMMA, G., BELLER, G., BIERMAN, F., DAVIS, J., DOUGLAS, P., FAXON, D., GILLAM, L., & KIMBALL, T. (2003) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(03)00685-0 · Cited by 107
Use of antioxidant supplements during breast cancer treatment: a comprehensive review
Greenlee, H., Hershman, D. L., & Jacobson, J. S. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0193-0 · Cited by 105
Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure
Tallaj, J. A., Franco, V., Rayburn, B. K., Pinderski, L. J., Benza, R. L., Pamboukian, S. V., Foley, B. A., & Bourge, R. C. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.12.108 · Cited by 100
Carvedilol in children with cardiomyopathy: 3-year experience at a single institution
Rusconi, P. G., Gómez-Marı́n, O., Rossique-González, M., Redha, E., Marín, J. R., Young, M., & Wolff, G. S. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2003.07.025 · Cited by 98
Does anthracycline administration by infusion in children affect late cardiotoxicity?
Levitt, G., Dørup, I., Sørensen, K. E., & Sullivan, I. D. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04803.x · Cited by 85
Cardiovascular Trials in Long-Term Survivors of Childhood Cancer
Lipshultz, S. E., & Colan, S. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.937 · Cited by 85
Self-citationCardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines
Lipshultz, S. E., Vlach, S. A., Lipsitz, S. R., Sallan, S. E., Schwartz, M. L., & Colan, S. D. (2005) · PEDIATRICS · doi:10.1542/peds.2004-1004 · Cited by 73
Self-citationCardioprotective interventions for cancer patients receiving anthracyclines
van Dalen, E. C., Caron, H. N., Dickinson, H., & Kremer, L. C. M. (2005) · doi:10.1002/14651858.cd003917.pub2 · Cited by 70
On behalf of the United Kingdom Children's Cancer Study Group (UKCCSG) New Agents and Société Française d'Oncologie Pédiatrique (SFOP) Pharmacology Group, Lowis, S. P., Lewis, I. J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603288 · Cited by 55
Bu'Lock, F. A., Mott, M. G., Oakhill, A., & Martin, R. P. (1999) · Pediatric Cardiology · doi:10.1007/s002469900459 · Cited by 45
Prevention of anthracycline-induced cardiotoxicity in children: The evidence
van Dalen, E. C., Caron, H. N., & Kremer, L. C. M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.040 · Cited by 42
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub2 · Cited by 41
Exercise rehabilitation of pediatric patients with cardiovascular disease
Miller, T. L., Horgan, S., & Lipshultz, S. E. (2005) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2004.12.002 · Cited by 32
Self-citation
Cited by
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Cardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citationCreutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Metadata
- Authors
- Lipshultz, S. E., Alvarez, J. A., & Scully, R. E.
- Venue
- Heart
- Publisher
- BMJ
- Published
- 2008-03-17
- Volume
- 94
- Issue
- 4
- Pages
- 525-533
- ISSN
- 1355-6037 (ISSN-L)
- 1468-201X
- OpenAlex
- W2125052019
- Cited by
- 379
- References
- 65
- FWCI
- 12.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.